Drug intelligence / Profile preview

AMATUSSiN

Development stage: Unknown
Lead developer: Zakład Farmaceutyczny AMARA
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

AMATUSSiN is a medical device in the form of a syrup developed by Zakład Farmaceutyczny AMARA. It is designed to protect and moisturize the mucous membranes of the mouth, throat, vocal cords, and larynx. The syrup contains natural plant extracts, including wild mallow leaf extract (*Malva sylvestris*), Icelandic lichen extract (*Cetraria islandica*), and linden flower extract (*Tilia vulgaris*), along with sodium hyaluronate and xanthan gum. These ingredients form a protective film that coats the mucous membranes, relieving dryness, burning, and sore throat, while also soothing dry cough and hoarseness.

Brand names: AMATUSSiN
Other names: Amatussin

Beyond the preview

Go deeper on AMATUSSiN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMATUSSiN.

Explore the full profile